Skip to main content
Log in

Abstract

More than 69 million Indians are suffering from diabetes, of which a substantial proportion of the population are currently holding or will seek in the future the license to drive. Driving essentially requires multitasking with visuospatial skills at the same time and thus the management of diabetes in individuals which should demonstrate a proper detection and treatment of diabetes-related hypoglycemia will predict the capacity of driving any motor vehicle. Repeated hypoglycemia-related neuroglycopenia causes increased risk of neurocognitive dysfunction leading to visuospatial skills deficiency. Eight percent of dementia may be attributed to diabetes. Potential causes of driving impairment associated with diabetes are acute hypoglycemia, and its unawareness, retinopathy, neuropathy related to foot that affects ability to use pedals, IHD, cerebrovascular disease, somnolence and sleep disorder associated with obesity, use of pain relieving medications and antidepressant, and cognitive dysfunction and thus should be reviewed properly before issuing a driving license. Medical evaluation and documentation of acute and chronic complications of drivers by a registered medical practitioner at pre-determined intervals may be considered as a legal necessity to identify at-risk drivers. Secretagogues have a higher incidence of hypoglycemia compared to someone who is on metformin alone. On the other hand, hypoglycemia is more frequent in an insulin-treated patient of both type 1 and type 2 diabetes. In many countries as well as in European Union (EU), it is necessary to review medical fitness in every 3 years by the authority; a person should not have any severe hypoglycemic event in preceding 12 months and a driver must have awareness of hypoglycemia and its management. According to Canadian diabetes association consensus statement, review should be done every 2 years; a person should not have any severe hypoglycemic event in preceding 6 months, and according to ADA position statement evaluation should be done every 2–5 years. Medical fitness certificate should be reviewed at frequent intervals; the authorities should enforce strict regulation on suspension and revocation of driving license. Information to the authorities should be promptly done by doctors or patients. Decision should be based on medical evaluation, but hypoglycemia that occurs due to medication change and during sleep does not warrant for disqualification as it may be corrected with proper dietary changes and dose adjustments. Any driver with suspended license should be re-assessed in the next 6 months for their medical fitness and hypoglycemic profile and if found suitable, the license can be revoked. Physicians should participate and should assess patient’s physical and mental status, medical condition and treatment, list of medications which may impair driving performance, and any disease-related complication that lead to impaired driving or dangerous driving. Patient education is the most important factor to prevent any motor accident related to their medical condition and should be trained to prevent acute and chronic complications of diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, Dunning T, et al Executive summary. In: IDF Diabetes Atlas. 7th ed. 2015. IDF Diabetes Atlas. 8th ed.

  2. Lorber D, Anderson J, Anderson J, Arent S, Cox DJ, Frier BM, et al. Diabetes and driving. Diabetes Care. 2012;35(1):S81–6.

    PubMed  Google Scholar 

  3. Cox DJ, Singh H, Lorber D. Diabetes and driving safety: science, ethics, legality and practice. Am J Med Sci. 2013;345(4):263–5.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, et al. Can J Diabetes. 2013;37:S61–8.

    Article  PubMed  Google Scholar 

  5. American Diabetes Association. Glycemic targets. In: Standards of Medical Care in Diabetes 2017. Diabetes Care. 2017;40(1): S48–S56).

  6. Bolo NR, Musen G, Jacobson AM, Weinger K, McCartney RL, Flores V, et al. Brain activation during working memory is altered in patients with type 1 diabetes during hypoglycemia. Diabetes. 2011;60:3256–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Duning T, Heuvel I, Dickmann A, Volkert T, Wempe C, Reinholz J, et al. Hypoglycemia aggravates critical illness–induced neurocognitive dysfunction. Diabetes Care. 2010;33:639–44.

    Article  PubMed  Google Scholar 

  8. Schizophrenia Library [Internet]. Randwick NSW, Australia: Schizophrenia Research Institute; 2016. Accessed on March 21, 2017; Available from: https://www.schizophreniaresearch.org.au/library/browse-library/signs-and-symptoms/cognition/visuospatial-ability

  9. Duarte JMN. Metabolic alterations associated to brain dysfunction in diabetes. Aging and Disease. 2015;6(5):304–21.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Heller SR, Campbell MJ, Amiel SA, Frier BM, Macleod K, Kerr D, et al. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–7.

    Article  Google Scholar 

  11. Kerr D, Olateju T. Driving with diabetes in the future: in-vehicle medical monitoring. J Diabetes Sci Technol. 2010;4(2):464–9.

    Article  PubMed  PubMed Central  Google Scholar 

  12. American Diabetes Association. Diabetes and driving. Diabetes Care 2014; 37 (Suppl 1): S97- S103.

  13. LeRoy AA. Morse ML. Analysis of Database. U.S. Department of Transportation: Multiple Medications and Vehicle Crashes; 2008. Available at https://ntl.bts.gov/lib/30000/30200/30202/810858.pdf. Accessed on March 19, 2017

  14. Signorovitch JE, Macaulay D, Diener M, Yan Y, EQ W, Gruenberger JB, et al. Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs. Diabetes. Obes Metab. 2013;15:335–41.

    Article  CAS  Google Scholar 

  15. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other anti-diabetes drugs and the risk of lactic acidosis or hypoglycemia. Diabetes Care. 2008;31:2086–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Inkster B, Frier BM. Diabetes and driving. Diabetes. Obes Metab. 2013:1–9.

  17. Houlden RL, Berard L, Cheng A, Kenshole AB, Silverberg J, Woo VC, et al. Diabetes and driving: 2015 Canadian Diabetes Association updated recommendations for private and commercial drivers. Can J Diabetes. 2015;39:347–53.

    Article  PubMed  Google Scholar 

  18. Lorber D, Anderson J, Anderson J, Arent S, Cox DJ, Frier BM, et al. Diabetes and driving. Diabetes Care. 2012;35(1):S81–6.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sujoy Ghosh.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghosh, S., Bajaj, S., Pandit, K. et al. Diabetes and driving. Int J Diabetes Dev Ctries 37, 400–406 (2017). https://doi.org/10.1007/s13410-017-0586-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13410-017-0586-x

Keywords

Navigation